In a recent study, both KDM6B and islet1 (ISL1) expressions were reduced in NAFLD, and they synergistically inhibited adipogenesis while promoting lipolysis. This evidence concerns the gene KDM6B and metabolic dysfunction-associated steatotic liver disease.